SecBot SecBot

QDEL

QuidelOrtho Corp
Nasdaq· In Vitro & In Vivo Diagnostic Substances· CIK 0001906324 Biotech & Drug Discovery
$13.63 −0.10 (−0.76%)
Oct 26 4:00 PM ET · prev $13.73
Market cap
$924.4M
Small cap
Median target
$12.00
−12% · range $12.00–20.00
Next earnings
Nov 3
in 8 days
1 year
−53.8%
from $29.48 · Oct 27
30 days
+25.8%
from $10.83
52-week range
$9.96–35.38
−61% from high · low May 11
Avg volume 20D
2.21M
shares / day
Short interest
14.95M
≈21.8% of shares · +5.4%
Days to cover
11.0
at average volume
Insider net
$0
no open-market trades · since May 29
New fund stakes
1
Q2 2026 13F · 2 exits
Filing reports
8
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 1 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 3, 2026
Strongest BULLISH FMR LLC (Fidelity) filed a Schedule 13G/A disclosing beneficial ownership of 3,950,167.67 shares of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since May 29. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 17 added (1 new), 13 trimmed or exited. Largest new: Van Lanschot Kempen Investment Management N.V $11.3M.

  • Short sellersSTEADY

    Short interest +5.4% to 14.95M shares. 11.0 days to cover, ≈21.8% of shares.

  • TrendUPTREND

    6% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
2
exits
$11.3M
in new stakes
FundMoveSharesValue
Neuberger Berman Group LLCDOUBLED3,534,619$62.1M
MORGAN STANLEYADD1,675,525$29.3M
DIMENSIONAL FUND ADVISORS LPTRIM1,253,683$22.0M
GOLDMAN SACHS GROUP INCTRIM1,064,744$18.6M
MILLENNIUM MANAGEMENT LLCDOUBLED722,480$12.7M
VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V.NEW647,069$11.3M
Creative PlanningDOUBLED187,386$3.3M
SEI INVESTMENTS COTRIM185,272$3.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 3 analysts

Price is inside the target range. Median implies −12%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Jul 8, 2026Citigroup
MAINTAIN
MAINTAINNeutral
Jul 1, 2026JP Morgan
MAINTAIN
MAINTAINUnderweight
May 7, 2026Jefferies
DOWNGRADE
DOWNGRADEHold
May 6, 2026Citigroup
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
open-market buys or sells · since May 29
DateInsiderTypeValue
Oct 15, 2026
Siegrist Jonathan Philip
EVP of R&D & CTO
EXERCISE18,657 sh
Oct 15, 2026
Siegrist Jonathan Philip
EVP of R&D & CTO
TAX W/H$93.1K
Sep 15, 2026
Bowman Ronald Lee
Chief Human Resources Officer
TAX W/H$9.8K
Sep 15, 2026
Bowman Ronald Lee
Chief Human Resources Officer
EXERCISE2,566 sh
Aug 15, 2026
Hanson Bryan Michael
EVP Global Port. Mgmt & Mkting
TAX W/H$2.3K
Aug 15, 2026
Hanson Bryan Michael
EVP Global Port. Mgmt & Mkting
EXERCISE446 sh
Jul 15, 2026
Young Micah W
Chief Financial Officer
AWARD356,555 sh
Jul 1, 2026
Hanson Bryan Michael
EVP Global Port. Mgmt & Mkting
TAX W/H$38.1K

Earnings setup

Estimates
Nov 3
reports in 8 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
14,953,442
shares short
+5.4%
vs prior settlement
11.0
days to cover
≈21.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Other
QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a l
Oct 15, 2026 Insider
Siegrist Jonathan Philip acquired via exercise 18,657 shares
EVP of R&D & CTO
Oct 15, 2026 Insider
Siegrist Jonathan Philip surrendered for taxes 6,695 shares
EVP of R&D & CTO @ $13.91 ($93.1K)
Oct 7, 2026 SEC
FMR LLC (Fidelity) filed a Schedule 13G/A disclosing beneficial ownership of 3,950,167.67 shares of QuidelOrtho Corp…
SC 13G/A — Impact 5/10
Sep 23, 2026 SEC
QuidelOrtho amended its existing credit agreement to reset financial covenant levels through a 'Covenant Relief…
8-K — Impact 6/10
Sep 15, 2026 Insider
Bowman Ronald Lee surrendered for taxes 921 shares
Chief Human Resources Officer @ $10.63 ($9.8K)
Jul 15, 2026 SEC
Micah Young, the new Chief Financial Officer of QuidelOrtho Corp, filed a Form 3 initial statement of beneficial…
3 — Impact 2/10
Jun 30, 2026 Inst.
Neuberger Berman Group LLC — DOUBLED
3,534,619 shares ($62.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
QDEL Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Oct 15, 2026
Press release
QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions…
Sep 24, 2026
Press release
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode…
Aug 27, 2026
Press release
Faster Answers, Better Decisions: ADLM 2026 Highlights
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released…
Aug 3, 2026
Earnings date
QDEL Q2 2026 Earnings Scheduled — 2026-08-03
Jul 15, 2026
Press release
QuidelOrtho Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL)("QuidelOrtho"), a leading global provider of diagnostic solutions…

SecBot reports

8 filings · 1 bullish · 2 bearish · 1 mixed · 4 neutral
All QDEL filing & press-release reports (8)